Search details
1.
Ubiquitin ligase COP1 coordinates transcriptional programs that control cell type specification in the developing mouse brain.
Proc Natl Acad Sci U S A
; 115(44): 11244-11249, 2018 10 30.
Article
in English
| MEDLINE | ID: mdl-30322923
2.
Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens.
Clin Immunol
; 187: 37-45, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29031828
3.
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Clin Cancer Res
; 13(12): 3713-23, 2007 Jun 15.
Article
in English
| MEDLINE | ID: mdl-17575237
4.
CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis.
PLoS One
; 13(1): e0190158, 2018.
Article
in English
| MEDLINE | ID: mdl-29320521
5.
Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Mol Cancer Ther
; 16(9): 1729-1738, 2017 09.
Article
in English
| MEDLINE | ID: mdl-28619758
6.
Cerebrospinal fluid rhinorrhea: diagnosis and management.
Otolaryngol Clin North Am
; 38(4): 597-611, 2005 Aug.
Article
in English
| MEDLINE | ID: mdl-16005720
7.
Immunohistochemical detection of FLAG-tagged endogenous proteins in knock-in mice.
J Histochem Cytochem
; 63(4): 244-55, 2015 04.
Article
in English
| MEDLINE | ID: mdl-25575566
8.
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.
Mol Cancer Ther
; 14(4): 931-40, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25637314
9.
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Mol Cancer Ther
; 13(5): 1078-91, 2014 May.
Article
in English
| MEDLINE | ID: mdl-24634413
10.
Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG.
MAbs
; 5(4): 540-54, 2013.
Article
in English
| MEDLINE | ID: mdl-23774668
11.
In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Thyroid
; 23(12): 1569-77, 2013 Dec.
Article
in English
| MEDLINE | ID: mdl-23705946
12.
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Mol Cancer Ther
; 10(12): 2298-308, 2011 Dec.
Article
in English
| MEDLINE | ID: mdl-21926191
13.
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Clin Cancer Res
; 16(13): 3507-16, 2010 Jul 01.
Article
in English
| MEDLINE | ID: mdl-20472683
Results
1 -
13
de 13
1
Next >
>>